|
1
|
Helwig EB: Atypical fibroxandioma: Proceedings of 18th annual tumor seminar of San Antonio society of pathologists. Tex State J Med. 59:664–667. 1961.
|
|
2
|
Patterson JW, Konerding H and Kramer WM: ‘Clear cell’ atypical fibroxanthoma. J Dertmatol Surg Oncol. 13:1109–1114. 1987.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Longacre TA, Smoller BR and Rouse RV: Atypical fibroxanthoma: Multiple immunohistologic profiles. Am J Surg Pathol. 17(1199)1993.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tardío JC, Pinedo F, Aramburu J, Martínez-González MÁ, Arias D, Khedaoui R, Suárez-Massa D and Santonja C: Clear cell atypical fibroxanthoma: Clinicopathological study of 6 cases and review of the literature with special emphasis on the differential diagnosis. Am J Dermatopathol. 38:586–592. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kemmerling R, Dietze O, Müller S and Neureiter D: Aspects of the differential diagnosis of clear-cell lesions of the skin in connection with the rare case of a clear-cell atypical fibroxanthoma. Pathol Res Pract. 205:365–370. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Murali R and Palfreeman S: Clear cell atypical fibroxanthoma-report of a case with review of the literature. J Cutan Pathol. 33:343–348. 2006.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cai JP and Randall B: HMB-45 expression in a clear cell variant of atypical fibroxanthoma. J Cutan Pathol. 33:186–188. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Crowson AN, Carlson-Sweet K, Macinnis C, Taylor JR, Battaglia T, LaMar WL, Minor D, Sutter S and Hill T: Clear cell atypical fibroxanthoma: A clinicopathologic study. J Cutan Pathol. 29:374–381. 2002.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Lazaro-Santander R, Andres-Gozalbo C, Rodriguez-Pereira C and Vera-Román JM: Clear cell atypical fibroxanthoma. Histopathology. 35:484–485. 1999.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Requena L, Sangueza OP, Yus ES and Furio V: Clear-cell atypical fibroxanthoma: An uncommon histopathologic variant of atypical fibroxanthoma. J Cutan Pathol. 24:176–182. 1997.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Javier CN, Colón DC, Sánchez JL and Sánchez JE: Clear-cell atypical fibroxanthoma: A combined immunohistochemistry analysis. Am J Dermatopathol. 38:775–779. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Nguyen CM, Chong K and Cassarino D: Clear cell atypical fibroxanthoma: A case report and review of the literature. J Cutan Pathol. 43:538–542. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Goldstein Z, Sarantopoulos G and Smart C: Clear-cell atypical fibroxanthoma: An unusual case in an unusual place. J Cutan Pathol. 44:951–953. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bedir R, Agirbas S, Sehitoglu I, Yurdakul C and Elmas O: Clear cell atypical fibroxantoma: A rare variant of atypical fibroxanthoma and review of the literature. J Clin Diagn Res. 8:FD09–FD11. 2014.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Beer T, Calonje E and Wick M: Atypical fibroxanthoma and variants. In: Elder D, Massi D, Scolyer R, Willemze R (eds): WHO classification of skin tumors. IARC Press, Lyon, 2018, pp368-369.
|
|
16
|
Helwig EB and May D: Atypical fibroxanthoma of the skin with metastasis. Cancer. 57:368–376. 1986.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Soleymani T and Hollmig ST: Conception and management of a poorly understood spectrum of dermatologic neoplasms: Atypical fibroxanthoma, pleomorphic dermal sarcoma, and undifferentiated pleomorphic sarcoma. Curr Treat Options Oncol. 18(50)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ang GC, Roenigk RK, Otley CC, Phillips PK and Weaver AL: More than 2 decades of treating atypical fibroxanthoma at mayo clinic: What have we learned from 91 patients? Dermatol Surg. 35:765–772. 2009.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mohanty SK, Sharma S, Pradhan D, Kandukuri SR, Farahani N, Barry C, Wu JM, Frishberg D and Balzer B: Microphthalmia- associated transcription factor (MiTF): Promiscuous staining patterns in fibrohistiocytic lesions is a potential pitfall. Pathol Res Pract. 214:821–825. 2018.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kanner WA, Brill LB II, Patterson JW and Wick MR: CD10, p63 and CD99 expression in the differential diagnosis of atypical fibroxanthoma, spindle cell squamous cell carcinoma and desmoplastic melanoma. J Cutan Pathol. 37:744–750. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Cesinaro AM, Gallo G, Tramontozzi S and Migaldi MJ: Atypical fibroxanthoma and pleomorphic dermal sarcoma: A reappraisal. J Cutan Pathol. 48:207–210. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Harding-Jackson N, Sangueza M, Mackinnon A, Suster S and Plaza JA: Spindle cell atypical fibroxanthoma: Myofibroblastic differentiation represents a diagnostic pitfall in this variant of AFX. Am J Dermatopathol. 370:509–514. 2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Soleymani T, Aasi SZ, Novoa R and Hollmig ST: Atypical fibroxanthoma and pleomorphic dermal sarcoma: Updates on classification and management. Dermatol Clin. 37:253–259. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Cooper JZ, Newman SR, Scott GA and Brown MD: Metastasizing atypical fibroxanthoma (cutaneous malignant histiocytoma): Report of five cases. Dermatol Surg. 31:221–225. 2005.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Miller K, Goodlad JR and Brenn T: Pleomorphic dermal sarcoma. Adverse histologic features predict aggressive behavior and allow distinction from atypical fibroxanthoma. Am J Surg Pathol. 36:1317–1326. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Helbig D, Quaas A, Mauch C, Merkelbach-Bruse S, Büttner R, Emberger M, Wobser M, Rüsseler V, Pütz K, Binot E, et al: Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget. 8:109457–109467. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, Carrera C, Schimming T, Möller I, Schwamborn M, et al: TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst. 106(dju246)2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Griewank KG, Wiesner T, Murali R, Pischler C, Müller H, Koelsche C, Möller I, Franklin C, Cosgarea I, Sucker A, et al: Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles. Mod Pathol. 31:418–428. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Helbig D, Ihle MA, Putz K, Tantcheva-Poor I, Mauch C, Büttner R and Quaas A: Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal scarcomas. Oncotarget. 7:21763–21774. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Dei Tos AP, Maestro R, Doglioni C, Gasparotto D, Boiocchi M, Laurino L and Fletcher CD: Ultraviolet-induced p53 mutations in atypical fibroxanthoma. Am J Pathol. 145:11–17. 1994.PubMed/NCBI
|
|
31
|
Soufir N, Ribojad M, Magnaldo T, Thibaudeau O, Delestaing G, Daya-Grosjean L, Rivet J, Sarasin A and Basset-Seguin NJ: Germline and somatic mutations of the INK4a-ARF gene in a xeroderma pigmentosum group C patient. J Invest Dermatol. 119:1355–1360. 2002.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Lee SM, Zhang W and Fernandez MP: Atypical fibroxanthoma arising in a young patient with Li-Fraumeni syndrome. J Cutan Pathol. 41:303–307. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Suárez-Vilela D, Izquierdo-García F, Domínguez-Iglesias F and Méndez-Álvarez JR: Combined papillated bowen disease and clear cell atypical fibroxanthoma. Case Rep Dermatol. 2:69–75. 2010.PubMed/NCBI View Article : Google Scholar
|
